[ad_1] RT @ThomasCiullaMD: Looking forward to discussing #drugdelivery and durability at OIS ASRS! #OIS #retina [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] RT @ModernRetina: Rahul Khurana, MD, offers updates and details about the Aaviate study, which is investigating a possibly once-and-done ge… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
RT @Biotech_Winners: Clearside Biomedical Suprachoroidal Delivery Technology to be Featured at Upcoming ASRS and OIS Medical Meetings https…
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] RT @RetinalPhys: Several posters about Clearside Biomedical’s suprachoroidal delivery platform, Xipere, and gene therapy delivery using Cle… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] RT @ThomasCiullaMD: Our clinical study, highlighting the need for better therapy, was picked up by Ophthalmology Advisor: Longer Term Anti-… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
Looking forward to discussing #drugdelivery and durability at OIS ASRS! #OIS #retina https://t.co/kkYEiiIS5r
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] Ophthalmology Management – SUPRACHOROIDAL INJECTIONS: XIPERE AND BEYOND https://t.co/kvNu5nnwrd [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] RT @ModernRetina: Survey respondents point to a perceived gap in treatments for uveitic macular edema, document interest in suprachoroidal… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
Recently published: https://t.co/5IyRrMAdlc “Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications”
Sustained release #drugdelivery may shift treatment paradigms & improve #glaucoma outcomes. #eye https://t.co/JLqoDGIu4W
[ad_2]
Source by Thomas Ciulla, MD, MBA